Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk - PubMed (original) (raw)

Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk

N H Shear et al. J Clin Invest. 1988 Dec.

Abstract

Arene oxide metabolites of aromatic anticonvulsants (phenytoin, phenobarbital, and carbamazepine) may be involved in the pathogenesis of hypersensitivity reactions. We investigated 53 patients with clinical sensitivity to anticonvulsants by exposing their lymphocytes in vitro to drug metabolites generated by a murine hepatic microsomal system. The diagnosis of a hypersensitivity reaction was corroborated by in vitro rechallenge for each drug (phenytoin, n = 34; phenobarbital, n = 22; carbamazepine, n = 25) when cytotoxicity (% dead cells) exceeded 3 SD above the mean result for controls. Cross-reactivity among the drugs was noted. 7 out of 10 patients who had received all three anticonvulsants had adverse reactions to each. 40 out of 50 patients tested to all three drugs in vitro were positive to each. Adverse reactions were indistinguishable among anti-convulsants. Skin rash (87%), fever (94%), hepatitis (51%), and hematologic abnormalities (51%) were common clinical features of each drug. 62% of reactions involved more than two organs. Cells from patients' parents exhibited in vitro toxicity that was intermediate between values for controls and patients. In vitro testing can help diagnose hypersensitivity to anticonvulsants. Cells from patients may also be used for prospective individualization of therapy to decrease risk of adverse reaction. Cross-reactivity among the major anticonvulsants is common and should be considered before deciding on alternative therapy.

PubMed Disclaimer

Cited by

Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries.
Medina-Cáliz I, Sanabria-Cabrera J, Villanueva-Paz M, Aukštikalnė L, Stephens C, Robles-Díaz M, Pinazo-Bandera JM, García-Cortes M, Conde I, Soriano G, Bessone F, Hernandez N, Nunes V, Paraná R, Lucena MI, Andrade RJ, Niu H, Alvarez-Alvarez I. Medina-Cáliz I, et al. Arch Toxicol. 2024 Jan;98(1):303-325. doi: 10.1007/s00204-023-03630-0. Epub 2023 Dec 5. Arch Toxicol. 2024. PMID: 38051367 Free PMC article.
Presumptive phenobarbital-induced systemic lupus erythematosus in a domestic dog.
Phillips E, Kornya M, Collier A, Barry M, Morrison K, Reggeti F. Phillips E, et al. J Vet Intern Med. 2023 Nov-Dec;37(6):2482-2487. doi: 10.1111/jvim.16882. Epub 2023 Sep 22. J Vet Intern Med. 2023. PMID: 37737539 Free PMC article.
DRESS syndrome: A literature review and treatment algorithm.
Calle AM, Aguirre N, Ardila JC, Cardona Villa R. Calle AM, et al. World Allergy Organ J. 2023 Apr 8;16(3):100673. doi: 10.1016/j.waojou.2022.100673. eCollection 2023 Mar. World Allergy Organ J. 2023. PMID: 37082745 Free PMC article. Review.
Drug Hypersensitivity Reactions in Patients with Cystic Fibrosis: Potential Value of the Lymphocyte Toxicity Assay to Assess Risk.
Abuzgaia AM, Elzagallaai AA, Mullowney T, Rieder MJ. Abuzgaia AM, et al. Mol Diagn Ther. 2023 May;27(3):395-403. doi: 10.1007/s40291-023-00644-3. Epub 2023 Mar 20. Mol Diagn Ther. 2023. PMID: 36939981
MD Investigation on the Interaction between Carbamazepine and Two CYP Isoforms, CYP3A4 and CYP3A5.
Liu S, Xu Y. Liu S, et al. Int J Mol Sci. 2023 Jan 22;24(3):2188. doi: 10.3390/ijms24032188. Int J Mol Sci. 2023. PMID: 36768510 Free PMC article.

References

1. Adv Neurol. 1975;11:355-68 - PubMed
1. Eur J Clin Pharmacol. 1987;31(6):633-41 - PubMed
1. Clin Exp Dermatol. 1982 Nov;7(6):585-91 - PubMed
1. Biochem Pharmacol. 1987 Mar 1;36(5):581-90 - PubMed
1. Drug Metab Dispos. 1982 Jan-Feb;10(1):1-10 - PubMed

Anticonvulsant hypersensitivity syndrome. In vitro assessment of risk - PubMed (original) (raw)